Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Current Assets (2016 - 2025)

Traws Pharma's Current Assets history spans 14 years, with the latest figure at $8.0 million for Q4 2025.

  • Quarterly results put Current Assets at $8.0 million for Q4 2025, down 68.02% from a year ago — trailing twelve months through Dec 2025 was $8.0 million (down 68.02% YoY), and the annual figure for FY2025 was $8.0 million, down 68.02%.
  • Current Assets for Q4 2025 was $8.0 million at Traws Pharma, down from $9.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $59.9 million in Q3 2021 to a low of $8.0 million in Q4 2025.
  • The 5-year median for Current Assets is $28.7 million (2023), against an average of $31.4 million.
  • The sharpest move saw Current Assets surged 180.18% in 2021, then crashed 68.02% in 2025.
  • Year by year, Current Assets stood at $55.4 million in 2021, then dropped by 29.01% to $39.3 million in 2022, then plummeted by 42.41% to $22.7 million in 2023, then rose by 10.11% to $25.0 million in 2024, then crashed by 68.02% to $8.0 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $8.0 million, $9.6 million, and $15.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.